Eli Lilly
Develops cardiometabolic, cancer, immunology, and neuroscience medicines led by tirzepatide.
$1,173.00
After-hours close−0.95 (−0.08%)
At close$1,173.95(−0.18%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | $9.85 | — | — |
| Aug 2026 | $6.40 | $8.38 | +30.9% |
| Apr 2026 | $6.97 | $8.55 | +22.7% |
| Feb 2026 | $6.91 | $7.54 | +9.1% |
| Oct 2025 | $5.69 | $7.02 | +23.4% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Aug 2021 | |||
| Apr 2021 | |||
| Jan 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Jan 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Jan 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| Apr 2017 | |||
| Jan 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Jan 2016 | |||
| Oct 2015 | |||
| Jul 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Oct 29, 2026 | $9.85 | — | — | $22.14B | — | — |
| Aug 5, 2026 | $6.40 | $8.38 | +30.9% | $20.82B | $22.97B | +10.3% |
| Apr 30, 2026 | $6.97 | $8.55 | +22.7% | $17.82B | $19.80B | +11.1% |
| Feb 4, 2026 | $6.91 | $7.54 | +9.1% | $17.94B | $19.29B | +7.5% |
| Oct 30, 2025 | $5.69 | $7.02 | +23.4% | $16.05B | $17.60B | +9.6% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 1, 2025 | ||||||
| Feb 6, 2025 | ||||||
| Oct 30, 2024 | ||||||
| Aug 8, 2024 | ||||||
| Apr 30, 2024 | ||||||
| Feb 6, 2024 | ||||||
| Nov 2, 2023 | ||||||
| Aug 8, 2023 | ||||||
| Apr 27, 2023 | ||||||
| Feb 2, 2023 | ||||||
| Nov 1, 2022 | ||||||
| Aug 4, 2022 | ||||||
| Apr 28, 2022 | ||||||
| Feb 3, 2022 | ||||||
| Oct 26, 2021 | ||||||
| Aug 3, 2021 | ||||||
| Apr 27, 2021 | ||||||
| Jan 29, 2021 | ||||||
| Oct 27, 2020 | ||||||
| Jul 30, 2020 | ||||||
| Apr 23, 2020 | ||||||
| Jan 30, 2020 | ||||||
| Oct 23, 2019 | ||||||
| Jul 30, 2019 | ||||||
| Apr 30, 2019 | ||||||
| Feb 6, 2019 | ||||||
| Nov 6, 2018 | ||||||
| Jul 24, 2018 | ||||||
| Apr 24, 2018 | ||||||
| Jan 31, 2018 | ||||||
| Oct 24, 2017 | ||||||
| Jul 25, 2017 | ||||||
| Apr 25, 2017 | ||||||
| Jan 31, 2017 | ||||||
| Oct 25, 2016 | ||||||
| Jul 26, 2016 | ||||||
| Apr 26, 2016 | ||||||
| Jan 28, 2016 | ||||||
| Oct 22, 2015 | ||||||
| Jul 23, 2015 | ||||||